Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ACP1 | P24666 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31044970 | 0.89 | MCHR1 (0.38) | MCHR1NPC1GALR3NR2F2RAB9A | |
| SCHEMBL31044669 | 0.86 | WNT3A (0.37) | NPC1GALR3NR2F2RAB9AACP1 | |
| SCHEMBL31044928 | 0.85 | RAB9A (0.35) | MCHR1NPC1GALR3NR2F2RAB9A | |
| SCHEMBL31045157 | 0.85 | MCHR1 (0.42) | MCHR1NPC1GALR3NR2F2RAB9A | |
| SCHEMBL31045167 | 0.84 | MCHR1 (0.44) | MCHR1NPC1GALR3NR2F2RAB9A | |
| SCHEMBL31044778 | 0.84 | CYP1A2 (0.34) | NPC1GALR3NR2F2RAB9APTGS2 | |
| SCHEMBL31044877 | 0.81 | ALDH1A1 (0.40) | NPC1GALR3NR2F2RAB9A | |
| SCHEMBL31045078 | 0.81 | KCNH2 (0.40) | NPC1GALR3NR2F2RAB9A | |
| SCHEMBL31044665 | 0.81 | METAP1 (0.38) | NPC1GALR3NR2F2RAB9AMAPT | |
| SCHEMBL31044704 | 0.80 | TRIM58 (0.40) | NPC1GALR3NR2F2RAB9AACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | FIMBRION THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | G6PD, SDHA, NQO1 | MCHR1 4749/4885NPC1 626/4885GALR3 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.